PitchFest 2017


Sponsored by

How Pitch Fest Works

A good pitch is the first step in the funding process!

At PitchFest, each entrepreneur will give a 10-minute pitch presentaion to a panel of experienced investors and business development specialists. This will be followed by 3 minutes of Q&A and 3 minutes of non-rebuttal feedback from the panel.

Each presentation will be evaluated and scored on a range of important business and scientific criteria. 

Leading scorers and winners will be announced during the keynote program on Thursday, May 11.

 

PITCHFEST 2017 PRESENTATION SCHEDULE

Wednesday, May 10

10:30AM EFFERENT LABS
Efferent Labs was founded in 2011 to delivery better, more informed healthcare to those in need through real-time monitoring of personal well-being. The core technology was invented by Dr. Spencer Rosero at the University of Rochester. Today, Efferent continues to make advancements with research teams at the University of Rochester as well as the University at Buffalo. Efferent has 4 issued patents with other patents pending and in the pipeline. Most recently, Efferent announced a development and commercialization agreement with Evotec AG.
Tower West
10:30AM

YIVIVA

Yiviva was founded in October 2015 by Yale University and Yung-Chi Cheng (PhD), Peikwen Cheng (MBA), Shwu-Huey Liu (PhD). Dr Cheng has discovered four approved drugs including the first drug for Hepatitis B (HBV) and Cytomegalovirus (CMV). Yiviva has licensed Yale and Dr Cheng's portfolio of breakthrough discoveries and technologies in botanical medicine to develop poly-target medicines to address complex diseases, including cancer and chronic diseases.

Hudson Room
11:00AM

MOTION INTELLIGENCE

Motion Intelligence Inc. was founded by Richard Uhlig in 2012. The company currently has 17 employees and is located in the Institute for Human Performance on the SUNY Upstate Medical University campus. The company has developed a clinical assessment system for concussion injuries (pending FDA clearance) and is developing epigenetic biomarkers for a variety of neurological disorders and injuries, including Autism Spectrum Disorder, Parkinson's Disease and Concussions. The company?s technology is developed in-house and through sponsored research agreements with several academic research institutions.

Tower West
11:00AM

INNOVENE

A NYC based company developing a new class of therapeutics derived from GRAS compounds. Innovene is now poised to introduce TriCurin - an anti-viral therapeutic against HPV and HPV originated cancers - into the cancer prevention & treatment marketplace. Founded in 2016, Patent owner: Research Foundation of the City University of New York and the Feinstein Institute for Medical Research. Innovene will have the exclusive license rights.

Hudson Room
11:30AM

BIOHARMONY THERAPEUTICS

Bioharmony Therapeutics, incorporated in 2016, is an early stage biotech startup focused on the development of novel antimicrobials, called lysins which are enzymes isolated from bacteriophages. Antibiotic resistance is a global public health problem leading to 700,000 deaths per year from infections that can no longer be treated with available antibiotics. Lysins, are the solution to this problem. Our first product is a topical lysin against MDR Acinetobacter baumannii infections in burn patients. Our pipeline includes lysins against pneumonia and UTI. Our technology is licensed from Rockefeller University. Our team has decades worth of experience in drug discovery and development.

Tower West
11:30AM

DELNOVA

DelNova, founded in 2016, is focused on applying drug delivery expertise for superior therapeutic benefit and a more competitive drug product profile. The first product under development is a repurposed drug, to be used for the reversal of undesirable side effects resulting from neurotoxin injections [ie. Botulinum type A toxin (BTX), e.g. Botox]. These undesirable side effects are evident in both cosmetic and medical applications. A rescue product has the potential to grow the $4 billion neurotoxin market. DelNova is seeking seed stage financing to progress preclinical studies to a human pilot study.

Hudson Room
1:30PM

INTENSITY THERAPEUTICS

Lewis H. Bender founded the company in 2012 based on his idea for a new way of treating cancer. The founder put his own money into the company to conduct the first experiments using contracted laboratories. After the first data set, friends, neighbors and family began to invest. The National Cancer Institute awarded the small company a CRADA in 2014 to help investigate the novel drug therapy. In less than 5 years since its founding, the company raised over $13.3 million, had two US patents granted, identified a lead drug from its novel platform, completed nonclinical studies, scaled GMP manufacturing, filed an accepted IND with FDA & a CTA with HC and began trials in 2017. The first human clinical study (US and Canada) is fully funded.

Tower West
1:30PM

CYTODEL

CytoDel's technology platform was developed by its NYU founders in response to a Tier 1 biodefense threat: weaponized botulinum neurotoxin (BoNT, aka Botox). Founded in 2012, CytoDel holds exclusive license to 5 issued US patents, issued foreign patents, and applications still under prosecution. The technology and manufacturing infrastructure is broadly applicable to large pharmaceutical markets. CytoDel's lead biodefense product, Cyto-111, is the first therapeutic ever shown to revere respiratory symptoms of botulism. It is being co-developed under a CRADA with DoD. An Animal Rule IND is planned by 2019, with revenue generation expected to commence by 2020.

Circle Room
2:00PM

CONQUERAB

The company has developed proprietary point of care devices and compositions for detection and mitigation of unwanted antibody (Ab) responses against therapeutic proteins. Those Ab responses can negatively impact drug efficacy and/or safety. ConquerAb's technology can be used to compare drugs marketed for the same application. An alpha prototype is available, which allows detection of anti-drug antibodies in one drop of blood.

Tower West
2:00PM

PARKSIDE SCIENTIFIC

Parkside designs and optimizes small molecule drug cures for deadly cancers (Triple-Negative Breast (TNBC) & Prostate) and other diseases (Inflammatory Bowel Disease (IBD), Diabetes, Obesity) by novel epigenetic approach of turning genes "on/off" through modulating protein signaling. Core competence is designing novel IP protected drugs, taking them to IND/Phase 1 Human Clinical Trials, and handing them off to larger pharma. Our most advanced program is for TNBC, which has no drug cure; existing Standard of Care is chemo/surgery.

Circle Room
2:30PM

HOCUSLOCUS

We are targeting the >$2BN cell line development market space, in particular manufacturing of biopharmaceuticals, with a cell line selection protocol that should speed up and lower the costs and efforts involved in creating a stable cell line. Our product, PTSelect, essentially replaces antibiotic resistance to perform selection with an siRNA. Selection is subsequently performed using transfected mRNA and magnetic isolation, depletion, FACS, or cell death. The techniques can also be used for cell separation of stem cells and other cell types for therapeutic purposes.

Tower West
2:30PM

PATHOVAX

Founded in 2014, PathoVax LLC is developing breakthrough vaccines against infectious diseases and cancers utilizing a Human Papillomavirus Virus-Like Particle (HPV VLP) platform that has been exclusively licensed from the Johns Hopkins University. This technology is generated by the same investigators responsible for existing HPV vaccines, and can be used to present other antigens to induce robust humoral or cellular immune responses against multiple infectious agents and tumors. Our lead candidate (RGVax) is a patented, universal HPV vaccine that targets all clinically-relevant HPVs while sidestepping uptake challenges to more than double a global market with over $2B in annual revenues.

Circle Room
3:15PM

VIRAZE

ViRAZE (UPenn PCI, 2015) discovers and develops first-in-class small molecules to treat virus-induced dermatology diseases. Our technology platform is based on inhibiting the DNA replication of viruses, with a legacy program for smallpox, which is funded by a $2 million NIH grant. Our lead commercial pre-clinical program is for the first approved drug to treat the painful and contagious skin disease Molluscum contagiosum, and is funded by a $3 million NIH grant. Current MC treatment relies on off-label drugs, and painful cauterization.

Tower West
3:15PM

FESARIUS THERAPEUTICS

The company has discovered and invented a scaffold technology that uses microspheres embedded in a collagen hydrogel to create and maximize the number of differential density interfaces within the scaffold. It is these differential density interfaces that drive the cell invasion into the scaffold.

Circle Room
3:45PM

VentriNova

VentriNova is a regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. VentriNova’s first generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue to stimulate proliferation of cardiac muscle cells.

  • No technology on the market or in clinical development, including stem cell-based technologies and other regenerative medicine applications, has the ability to grow new heart muscle cells in the diseased heart.

  • VentriNova’s pioneering science and technology is centered on development of biologic and small molecule regulators of the cyclin A2 gene – the key switch mediating heart cell division.

  • VentriNova’s technology demonstrated in both small and large animals the ability to control the modulation (increased gene expression) of the cyclin A2 gene, therefore stimulating endogenous growth of new myocytes (heart muscle cells).

  • VentriNova’s VN-100 technology is the conductor that orchestrates existing human heart
    cells to divide and regenerate themselves – a cellular function that is silenced in early human development.

Tower West
3:45PM

SCITECH DEVELOPMENT

Our lead compound is an accelerated, short-development track, anti-cancer agent (nano-fenretinide) delivered in a novel, intravenous system initially for the management of an orphan lymphoma (cutaneous T-Cell) and then for a cadre of other tumor-types of unmet need. Originally associated with the Karmanos Cancer Institute (KCI) and Wayne State University (WSU), SciTech was tasked with addressing the therapeutic performance limitations of fenretinide namely, the inability to deliver effective doses safely.

Circle Room
4:15PM

PAINQX

Founded in 2015, PainQx has developed an accurate, objective and reproducible method to measure pain in humans. PQx's patented technology delivers a real-time pain score to clinical users via cloud-based software on a pay-per-use or subscription basis. The output is directly correlated to a patient?s pain state. The system is currently being used by researchers to assess pain as a primary or secondary clinical end point to measure therapeutic efficacy. Upon FDA clearance, PainQx will work with hospitals, physicians and pain centers who serve chronic pain patients. There are over 116 million chronic pain patients in the US alone.

Tower West
4:15PM

MOUSENSOR

Mousensor, LLC is founded in 2016 by Dr. Paul Feinstein, a CUNY Neuroscience Professor and world expert in the molecular biology of olfaction and Dr. Charlotte D'Hulst, a specialist in bio-engineering and co-developer of the platform. The MouSensor technology is patent-pending and was published in Cell Reports in 2016. MouSensor, LLC won the "Best Team" award during the 2015 NYCRIN-NSF Innovation Corps and the start-up is a proud alum of the prestigious, competitive entry ELabNYC program. The company submitted its first SBIR Phase I to NSF and recently received its non-dilutive funding from the Michael J Fox Foundation.

Circle Room